Around 1,000 women a year in England with HER2-low advanced breast cancer will now receive the targeted drug Enhertu through the National Health Service (NHS), following a breakthrough on pricing between regulators and pharmaceutical firms AstraZeneca and Daiichi Sankyo. The UK health regulator NICE (National Institute for Health and Care Excellence), which had rejected the drug as too costly in July 2024, reversed its decision after fresh negotiations produced what it described as a "commercial solution." Clinical trials showed Enhertu nearly doubled progression-free survival compared with standard chemotherapy and extended overall survival by around six and a half months, a result advocates say will give patients precious additional time with their families.